Skip to main content

ColdZyme® Mouth Spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions

Davison, Glen, Perkins, Eleanor, Jones, Arwel W., Swart, Gabriella M., Jenkins, Alex R., Robinson, Hayley, Dargan, Kimberly (2020) ColdZyme® Mouth Spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions. European Journal of Sport Science, . ISSN 1746-1391. (doi:10.1080/17461391.2020.1771429) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:81826)

PDF Author's Accepted Manuscript
Language: English

Restricted to Repository staff only until 17 May 2021.
Contact us about this Publication
[img]
Official URL
https://doi.org/10.1080/17461391.2020.1771429

Abstract

Upper respiratory tract infection (URTI) can compromise athlete preparation and performance, so countermeasures are desirable. The aim of this study was to assess the effects of ColdZyme® Mouth Spray (ColdZyme) on self-reported upper respiratory tract infection in competitive endurance athletes under free-living conditions. One hundred and twenty-three endurance-trained, competitive athletes (recruited across 4 sites in England, UK) were randomised to control (no treatment, n = 61) or ColdZyme (n = 62) for a 3-month study period (between December 2017 – February 2018; or December 2018 – April 2019). They recorded daily training and illness symptoms (Jackson common cold questionnaire) during the study period. A total of 130 illness episodes were reported during the study with no difference in incidence between groups (episodes per person: 1.1 ± 0.9 Control, 1.0 ± 0.8 ColdZyme, P = 0.290). Episode duration was significantly shorter in ColdZyme compared to Control: Control 10.4 ± 8.5 days vs ColdZyme 7.7 ± 4.0 days, P = 0.016). Further analysis to compare episodes with poor vs good compliance with ColdZyme instructions for use (IFU) within the ColdZyme group showed a further reduction in duration of URTI when compliance was good (9.3 ± 4.5 days in ColdZyme poor IFU compliance vs 6.9 ± 3.5 days in ColdZyme good IFU compliance, P = 0.040). ColdZyme may be an effective countermeasure to reduce URTI duration, which was significantly lower (by 26-34%) in the ColdZyme treatment group (with no influence on incidence). This may have implications for athlete performance.

Item Type: Article
DOI/Identification number: 10.1080/17461391.2020.1771429
Uncontrolled keywords: Common Cold, Illness, Training, Exercise, Immunology, Countermeasure
Subjects: G Geography. Anthropology. Recreation > GV Recreation. Leisure > Sports sciences
R Medicine
Divisions: Faculties > Sciences > School of Sport and Exercise Sciences
Depositing User: Glen Davison
Date Deposited: 23 Jun 2020 09:06 UTC
Last Modified: 23 Jun 2020 10:20 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/81826 (The current URI for this page, for reference purposes)
Davison, Glen: https://orcid.org/0000-0003-4340-0074
  • Depositors only (login required):

Downloads

Downloads per month over past year